Just two injections a year... South Africa invests $72 million to combat Ebola

Written by Omnia Hassan:

In what is considered one of the largest health initiatives in its modern history, South Africa announced Africa  1.3 billion rand, equivalent to about $72 million, has been allocated to launch the HIV prevention drug “Linakapavir” on a large scale.

This comes in an attempt to reduce new infections and gradually eliminate its classification as the country with the highest number of people infected with the virus globally.

The new program represents a strategic shift in disease control efforts, as the government is relying on the latest medical innovations to enhance prevention and reach the most vulnerable groups.

A revolutionary drug that changes the rules of prevention

Linacabavir has garnered widespread global attention as the first drug of its kind to work by disrupting the virus's outer shell and preventing it from multiplying inside the body.

Its importance lies in the fact that it is given through only two injections per year, making it a practical alternative to daily doses, which often face challenges related to commitment and continuity.

International clinical trials, including research sites in South Africa and Uganda, have shown efficacy rates approaching 100% in preventing infection, leading health experts to describe it as one of the most significant medical breakthroughs in the fight against HIV in recent years.

Targeting the most vulnerable groups

Health authorities plan to launch the first phase of the program across 360 public clinics spread across 24 regions experiencing high infection rates.

The plan focuses on adolescent girls, young women and pregnant women, as they are among the groups most vulnerable to the virus, with an ambitious goal of reaching about one million beneficiaries by the end of 2027.

International partnership to support financing

The project relies on a combination of government funding and international support, with the participation of global health organizations including the Global Fund and the Children's Investment Fund Foundation.

South African President Cyril Ramaphosa stressed that access to life-saving medicines should be a right available to everyone, not a privilege for limited groups.

Cost challenges and local manufacturing plans

Despite the widespread welcome for the initiative, the cost of the drug remains one of the biggest challenges to its rapid expansion.

Therefore, South Africa is banking on licensing agreements that will allow for the production of low-cost generic versions by 2027, as part of a broader African trend aimed at boosting local pharmaceutical manufacturing and reducing reliance on imports.

With the launch of the program, South Africa hopes that “Linakapavir” will be a real turning point in the fight against HIV, and will open the door to a new phase of control over one of the most complex health challenges in the African continent.